MX2022009762A - Moduladores del purinorreceptor 3 p2x (p2x3). - Google Patents
Moduladores del purinorreceptor 3 p2x (p2x3).Info
- Publication number
- MX2022009762A MX2022009762A MX2022009762A MX2022009762A MX2022009762A MX 2022009762 A MX2022009762 A MX 2022009762A MX 2022009762 A MX2022009762 A MX 2022009762A MX 2022009762 A MX2022009762 A MX 2022009762A MX 2022009762 A MX2022009762 A MX 2022009762A
- Authority
- MX
- Mexico
- Prior art keywords
- modulators
- purinereceptor
- disorders
- diseases
- compounds
- Prior art date
Links
- 102000000033 Purinergic Receptors Human genes 0.000 title 1
- 108010080192 Purinergic Receptors Proteins 0.000 title 1
- 102100040460 P2X purinoceptor 3 Human genes 0.000 abstract 2
- 101710189970 P2X purinoceptor 3 Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Burglar Alarm Systems (AREA)
- Amplifiers (AREA)
- Oscillators With Electromechanical Resonators (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062977008P | 2020-02-14 | 2020-02-14 | |
| PCT/IB2021/000091 WO2021161105A1 (en) | 2020-02-14 | 2021-02-12 | P2x3 modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022009762A true MX2022009762A (es) | 2022-09-09 |
Family
ID=77292083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022009762A MX2022009762A (es) | 2020-02-14 | 2021-02-12 | Moduladores del purinorreceptor 3 p2x (p2x3). |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12655145B2 (enExample) |
| EP (1) | EP4103564A4 (enExample) |
| JP (1) | JP2023513373A (enExample) |
| KR (1) | KR20220141331A (enExample) |
| CN (2) | CN115413279A (enExample) |
| AU (1) | AU2021219097A1 (enExample) |
| BR (1) | BR112022015858A2 (enExample) |
| CA (1) | CA3170664A1 (enExample) |
| IL (1) | IL295393A (enExample) |
| MX (1) | MX2022009762A (enExample) |
| WO (1) | WO2021161105A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3880678T3 (da) | 2018-11-13 | 2025-06-10 | Glaxosmithkline Intellectual Property No 3 Ltd | Krystallinske former af p2x3-modulator methyl(s)-2-((2-(2,6-difluoro-4-(methylcarbamoyl )phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholin-4-carboxylat |
| CA3131312A1 (en) | 2019-02-25 | 2020-09-03 | Bellus Health Cough Inc. | Treatment with p2x3 modulators |
| BR112022015818A2 (pt) * | 2020-02-14 | 2022-10-25 | Bellus Health Cough Inc | Preparação de um antagonista de p2x3 |
| CN113754654A (zh) * | 2020-06-05 | 2021-12-07 | 武汉人福创新药物研发中心有限公司 | 咪唑并吡啶类化合物及其用途 |
| WO2022156783A1 (zh) * | 2021-01-22 | 2022-07-28 | 武汉人福创新药物研发中心有限公司 | 咪唑并吡啶类化合物的制备方法及其中间体 |
| WO2022156784A1 (zh) * | 2021-01-22 | 2022-07-28 | 武汉人福创新药物研发中心有限公司 | 杂环类化合物的制备方法及其中间体 |
| WO2022161462A1 (zh) * | 2021-01-29 | 2022-08-04 | 上海海雁医药科技有限公司 | 吗啉衍生物及其药物组合物和用途 |
| WO2023020156A1 (zh) * | 2021-08-20 | 2023-02-23 | 苏州璞正医药有限公司 | 一种咪唑并吡啶衍生物的p2x3受体选择性调节剂及其药物用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2442797T3 (es) * | 2009-11-18 | 2014-02-13 | Neomed Institute | Compuestos de benzoimidazol y sus utilizaciones |
| KR102120513B1 (ko) | 2013-01-31 | 2020-06-08 | 네오메드 인스티튜트 | 이미다조피리딘 화합물 및 이의 용도 |
| US9907795B2 (en) * | 2016-01-08 | 2018-03-06 | Nerre Therapeutics Limited | Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents |
| US10111883B1 (en) | 2017-09-18 | 2018-10-30 | Bellus Health Cough Inc. | Selective P2X3 modulators |
| IL282087B2 (en) | 2018-10-10 | 2025-11-01 | Bellus Health Cough Inc | 4-(imidazo[1,2-a]pyridin-3-yl)-benzamide derivatives for treating pruritus |
| KR102797127B1 (ko) * | 2018-12-29 | 2025-04-21 | 우한 크리에이터나 사이언스 앤드 테크놀로지 컴퍼니, 리미티드 | 헤테로고리계 화합물, 중간체, 이의 제조 방법 및 용도 |
| CA3131312A1 (en) | 2019-02-25 | 2020-09-03 | Bellus Health Cough Inc. | Treatment with p2x3 modulators |
| CN112409331B (zh) * | 2019-08-21 | 2024-02-20 | 上海翰森生物医药科技有限公司 | 杂环类衍生物抑制剂、其制备方法和应用 |
| CN113754654A (zh) | 2020-06-05 | 2021-12-07 | 武汉人福创新药物研发中心有限公司 | 咪唑并吡啶类化合物及其用途 |
| WO2022001820A1 (zh) | 2020-06-29 | 2022-01-06 | 武汉朗来科技发展有限公司 | 杂环类化合物的晶型及其制备方法和应用 |
| WO2022156783A1 (zh) | 2021-01-22 | 2022-07-28 | 武汉人福创新药物研发中心有限公司 | 咪唑并吡啶类化合物的制备方法及其中间体 |
| WO2022156784A1 (zh) | 2021-01-22 | 2022-07-28 | 武汉人福创新药物研发中心有限公司 | 杂环类化合物的制备方法及其中间体 |
-
2021
- 2021-02-12 JP JP2022548875A patent/JP2023513373A/ja not_active Ceased
- 2021-02-12 EP EP21754440.2A patent/EP4103564A4/en active Pending
- 2021-02-12 KR KR1020227031507A patent/KR20220141331A/ko not_active Ceased
- 2021-02-12 AU AU2021219097A patent/AU2021219097A1/en not_active Abandoned
- 2021-02-12 IL IL295393A patent/IL295393A/en unknown
- 2021-02-12 BR BR112022015858A patent/BR112022015858A2/pt not_active IP Right Cessation
- 2021-02-12 WO PCT/IB2021/000091 patent/WO2021161105A1/en not_active Ceased
- 2021-02-12 CN CN202180028882.0A patent/CN115413279A/zh active Pending
- 2021-02-12 CN CN202411099037.4A patent/CN119039290A/zh active Pending
- 2021-02-12 CA CA3170664A patent/CA3170664A1/en active Pending
- 2021-02-12 US US17/929,035 patent/US12655145B2/en active Active
- 2021-02-12 MX MX2022009762A patent/MX2022009762A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN115413279A (zh) | 2022-11-29 |
| US20230312557A1 (en) | 2023-10-05 |
| EP4103564A1 (en) | 2022-12-21 |
| KR20220141331A (ko) | 2022-10-19 |
| JP2023513373A (ja) | 2023-03-30 |
| BR112022015858A2 (pt) | 2022-10-25 |
| US12655145B2 (en) | 2026-06-16 |
| AU2021219097A1 (en) | 2022-09-01 |
| CN119039290A (zh) | 2024-11-29 |
| EP4103564A4 (en) | 2024-05-01 |
| WO2021161105A1 (en) | 2021-08-19 |
| IL295393A (en) | 2022-10-01 |
| CA3170664A1 (en) | 2021-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP21086429A (es) | Moduladores de la vía integrada del estrés | |
| CO2024000588A2 (es) | Composiciones y métodos para la inhibición de ras | |
| CL2022001178A1 (es) | Ligandos de la pseudoquinasa tyk2 | |
| ECSP20069418A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CL2021000875A1 (es) | Moduladores de profármacos de la vía de estrés integrada | |
| CO2024013744A2 (es) | Moduladores de nlrp3 | |
| CL2018003142A1 (es) | Moduladores de la vía de estrés integrada | |
| MX2020004555A (es) | Moduladores de la vía de estrés integrada. | |
| MX2020004551A (es) | Moduladores de la vía de estrés integrada. | |
| MX2020004557A (es) | Moduladores de la vía de estrés integrada. | |
| MX2020004537A (es) | Moduladores de la vía integrada del estrés. | |
| MX2022000646A (es) | Derivados de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-4 ,5,6,7- tetrahidrobenzofuran-2-sulfonamida y compuestos relacionados como moduladores de nlpr3 para el tratamiento de esclerosis múltiple (ms). | |
| CO2022014499A2 (es) | Moduladores de nlrp3 | |
| MX2021008941A (es) | Moduladores gpr35. | |
| BR112021019070A2 (pt) | Ligantes de pseudoquinase tyk2 | |
| BR112022000855A2 (pt) | Moduladores de nlrp3 | |
| CL2024001566A1 (es) | Moduladores de la vía integrada del estrés | |
| CR20190468A (es) | Métodos para tratar enfermedades y trastornos mediados por completo | |
| BR112022009710A2 (pt) | Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2 | |
| ECSP21003171A (es) | Dinucleótidos cíclicos como agonistas de sting | |
| BR112021010856A2 (pt) | Vibegron para o tratamento de sintomas de bexiga hiperativa | |
| CL2020002398A1 (es) | Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd") | |
| CL2023000234A1 (es) | Moduladores de la vía de estrés integrada |